15 years of revenue, profit, cash flow and balance-sheet history through FY2025,
from SEC filings — with a computed, factual read of the trend.
Updated Overview →
Growth & profitability
Revenue has grown 5.1% per year over the past 5 years.
Net income has grown faster than revenue (7.7% vs 5.1% per year).
Operating margin has expanded, at 18.2% in the latest year.
Free cash flow has grown 5.3% per year over the past 5 years.
Financial health
Total debt ($12.9B) exceeds cash ($8.5B); net debt is $4.4B.
Total debt has grown slower than revenue (-7.2% vs 5.1% per year).
Operating income covered interest expense 16× in the latest year.
Total debt is 1.6× EBITDA.
Shareholder returns
Dividends have been paid for 12 consecutive years, consuming 63.1% of earnings and 55.7% of free cash flow.
The dividend has grown 10.0% per year over the past 5 years.
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key annual figures
FY
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
2025
$44.3B
$6.5B
56.4%
18.2%
12.5%
7.5%
$7.4B
$12.9B
$8.5B
2024
$42.0B
$13.4B
55.4%
16.3%
28.1%
16.5%
$6.4B
$14.1B
$7.6B
2023
$40.1B
$5.7B
55.2%
16.2%
14.8%
7.8%
$5.1B
$14.7B
$6.9B
2022
$43.7B
$6.9B
56.1%
19.2%
18.9%
9.3%
$7.8B
$16.8B
$9.9B
2021
$43.1B
$7.1B
57.0%
19.6%
19.8%
9.4%
$8.6B
$18.1B
$9.8B
2020
$34.6B
$4.5B
56.6%
15.5%
13.7%
6.2%
$5.7B
$18.7B
$6.8B
2019
$31.9B
$3.7B
58.5%
14.2%
11.9%
5.4%
$4.5B
$18.1B
$3.9B
2018
$30.6B
$2.4B
58.4%
11.9%
7.8%
3.5%
$4.9B
$19.6B
$3.8B
2017
$27.4B
$477M
54.7%
5.7%
1.5%
0.6%
$4.4B
$27.9B
$9.4B
2016
$20.9B
$1.4B
56.4%
14.5%
6.8%
2.7%
$2.1B
$22.0B
$18.6B
2015
—
$4.4B
—
—
20.9%
10.7%
$1.9B
$9.0B
$5.0B
2014
—
$2.3B
—
—
10.6%
5.5%
$2.6B
$7.8B
$4.1B
2013
—
$2.6B
—
—
10.2%
6.0%
$2.2B
$6.6B
$3.5B
2012
—
$6.0B
—
—
22.3%
8.9%
$7.5B
$20.5B
$10.8B
2011
—
$4.7B
—
—
19.3%
7.8%
$7.5B
$15.4B
$6.8B
Revenue & net income
RevenueNet income
Margins (gross / operating / net)
GrossOperatingNet
Return on equity & assets (ROE / ROA)
ROEROA
Free cash flow (CFO − capex, quarterly)
Free cash flow
Cash vs total debt
CashTotal debt
Cash flow: operating / investing / financing
OperatingInvestingFinancing
Key quarterly figures
Quarter
Revenue
Net income
Gross M
Op M
ROE
ROA
FCF
Total debt
Cash
Mar '26
$11.2B
$1.1B
56.2%
12.0%
2.1%
1.0%
$916M
$34.0B
$6.8B
Dec '25
$11.5B
$1.8B
57.0%
19.6%
3.4%
2.0%
$2.6B
$12.9B
$8.5B
Sep '25
$11.4B
$1.6B
55.4%
18.1%
3.2%
2.0%
$2.3B
$12.9B
$7.5B
Jun '25
$11.1B
$1.8B
56.4%
18.4%
3.5%
2.1%
$1.5B
$13.4B
$7.0B
Mar '25
$10.4B
$1.3B
56.9%
16.3%
2.7%
1.6%
$933M
$13.2B
$6.5B
Dec '24
$11.0B
$9.2B
55.0%
17.4%
19.4%
11.3%
$2.1B
$14.1B
$7.6B
Sep '24
$10.6B
$1.6B
55.8%
17.5%
4.1%
2.2%
$2.1B
$15.0B
$7.6B
Jun '24
$10.4B
$1.3B
55.6%
16.1%
3.3%
1.8%
$1.4B
$14.8B
$7.0B
Mar '24
$10.0B
$1.2B
55.2%
13.9%
3.2%
1.7%
$627M
$14.6B
$6.3B
Dec '23
$10.2B
$1.6B
55.5%
17.4%
4.1%
2.2%
$2.3B
$14.7B
$6.9B
Sep '23
$10.1B
$1.4B
54.6%
16.2%
3.8%
2.0%
$1.3B
$15.5B
$6.7B
Jun '23
$10.0B
$1.4B
55.1%
15.5%
3.7%
1.9%
$696M
$16.8B
$7.8B
Mar '23
$9.7B
$1.3B
55.6%
15.5%
3.6%
1.8%
$763M
$16.9B
$9.2B
Dec '22
$10.1B
$1.0B
54.5%
12.9%
2.8%
1.4%
$1.7B
$16.8B
$9.9B
Sep '22
$10.4B
$1.4B
55.5%
17.0%
4.0%
2.0%
$2.3B
$16.4B
$9.6B
Jun '22
$11.3B
$2.0B
56.2%
21.1%
5.5%
2.7%
$2.0B
$16.8B
$8.9B
Mar '22
$11.9B
$2.4B
58.1%
24.5%
6.9%
3.3%
$1.7B
$17.1B
$7.7B
Dec '21
$11.5B
$2.0B
58.4%
20.7%
5.6%
2.6%
$2.5B
$18.1B
$9.8B
Sep '21
$10.9B
$2.1B
59.5%
23.3%
6.1%
2.8%
$2.2B
$18.4B
$9.3B
Jun '21
$10.2B
$1.2B
51.6%
13.6%
3.5%
1.6%
$1.7B
$18.5B
$8.7B
Valuation over time
How the market has priced ABT against its own fundamentals since 2023-03 —
each month-end's share price set against the most recent annual filing, so the multiple moves
as price runs ahead of (or behind) earnings. Split-adjusted.
The price-to-earnings ratio has risen from 25.4× (Mar '23) to 29.4× (Nov '26).
The price-to-sales ratio has risen from 4.0× (Mar '23) to 4.3× (Nov '26).
The dividend yield has risen from 1.9% (Mar '23) to 2.1% (Nov '26).
Price / earnings (P/E)
P/E
Price / sales (P/S)
P/S
Dividend yield (%)
Dividend yield %
Frequently asked questions
Is ABT growing its revenue and profit?
Over the past 5 years, Abbott Laboratories's revenue has grown 5.1% per year, and net income grown 7.7% per year. These are computed facts, not advice.
How much debt does ABT have?
As of FY2025, Abbott Laboratories reported $12.9B of total debt against $8.5B of cash; operating income covered interest expense 16×.
What is ABT's profit margin?
In FY2025, gross margin was 56.4%, operating margin 18.2%, and net margin 14.7%.
What is ABT's P/E ratio?
Abbott Laboratories's P/E (TTM) is 30.61 as of the 2026-11-02 close — market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year, the same figure as on the ABT stock page. The valuation chart above sets each month-end's price against the latest annual net income instead, so its latest point (about 29.4× as of Nov '26) can differ. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested ·
growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price
against the latest annual filing. Informational only — not investment advice.